Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC)

Summary

The study is designed as a multicenter, double blind, parallel-group, placebo-controlled, randomized, event driven Phase II study of DTIC with or without bosentan as first-line treatment in patients with stage IV melanoma.

Timeline

Start

2005-09-30

Primary completion

2008-02-29

Completion

2008-02-29

Publications

• Kefford RF, Clingan PR, Brady B, Ballmer A, Morganti A, Hersey P. A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy. Mol Cancer. 2010 Mar 30;9:69. doi: 10.1186/1476-4598-9-69.

Drugs

Indications